August 22, 2024 01:12 PM EDT

Liquidia sues FDA over exclusivity decision to delay Yutrepia's full approval

Katherine Lewin

News Reporter

Liquidia has filed a lawsuit against the FDA over its decision to grant three years of exclusivity to United Therapeutics’ drug Tyvaso, which competes against …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Liquidia sues FDA over exclusivity decision to delay Yutrepia's full approval

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Moderna plans $1.1B in R&D and program cuts, delays break-even point to 2028

Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

Charles River to lay off 3% of staffers as it streamlines spending

Fulcrum's Phase 3 for old GSK drug fails, stock sinks

Sanofi buys into radiopharmaceutical field with $110M upfront, going after space held by Novartis

A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round

Liq­uidia sues FDA over ex­clu­siv­i­ty de­ci­sion to de­lay Yutrepi­a's full ap­proval

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Liquidia sues FDA over exclusivity decision to delay Yutrepia's full approval